Abstract: Presented are concepts for generating a subject-specific user interface for Clinical Decision Support. Once such concept comprises obtaining clinical reference information regarding established clinical knowledge, and also obtaining subject-specific clinical information regarding a subject. Clinical context information which describes a relevance or importance of at least one of a plurality of different clinical standards is determined. Based on the clinical reference information, the subject-specific clinical information and the clinical context information, a subset of the subject-specific clinical information relevant to a clinical decision is determined. At least one of: a user-interface component; and a user-interface element is defined based on the subset of the subject-specific clinical information.

Abstract: The invention relates to clinical decision support tool for supporting a decision based on a plurality of medical findings. The decision to be taken is by a multi-disciplinary team. The medical findings are based on different data sources and integrated to determine a complexity score, based on a consensus and/or conclusiveness of the medical findings. The medical findings and the complexity of the decision are displayed. A circular icon is used to display this information in an intuitive and simple manner. Multiple icons can be combined to arrive at a complexity score of a TNM staging decision.

Abstract: Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a 19F MR contrast agent. Preferably, the carrier also acts as a contrast enhancement agent for MRI based on the principle of Chemical Exchange-dependent Saturation Transfer (CEST). To this end the shell encloses a cavity that comprises a paramagnetic chemical shift reagent, a pool of proton analytes, and the 19F contrast agent, and wherein the shell allows diffusion of the proton analytes.

Abstract: Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T1/T2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.

Abstract: Disclosed are carriers for drugs and/or MR imaging agents having a lipid bilayer shell comprising a phospholipid having two terminal alkyl chains, one being a short chain having a chain length of at most seven carbon atoms, the other being a long chain having a chain length of at least fifteen carbon atoms. The mixed long/short chain phospholipids serve to tune the release properties of the carrier. Preferred phospholipids are phosphatidylcholines.

Abstract: Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T1/T2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.

Abstract: The invention relates to a method of releasing chemical compounds. The method includes distributing containers encapsulating a chemical compound over hair, said containers being configured to release the chemical compound upon reaching a transition temperature, and heating the hair to a predetermined temperature equal to or higher than the transition temperature. The heating of the hair enables heat transfer from the hair to one or more of the containers that are in proximity of the hair,whereby the one or more containers reach the transition temperature and release the chemical compound. In this manner, only those containers that are in close proximity to the hair can be heated up to their transition temperature and release the compound. Consequently, the compound is only released locally where the hair is present, while other skin areas where the hair is not present are protected against the potentially negative side effects of the compound.

Abstract: Disclosed are lipidomimetic compounds of formula I (I) wherein: G represents a group satisfying formula II: HO—CH2—{CH(OH)—CH2-0}m-CH2—{C(=0)-0-CH2})q— formula II each n independently is an integer from 1-30; m is an integer from 1-10; q is 0 or 1. These compounds can be added to the lipid bilayer of thermosensitive liposomes, for the purpose of aiding in the prevention of leakage of the liposomes' contents at 37° C., and retarding clearance from circulation.

Abstract: Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with 5 the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T 1/T 2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.

Abstract: Disclosed are lipidomimetic compounds of formula I (I) wherein: G represents a group satisfying formula II: HO—CH2—{CH(OH)—CH2-0}m-CH2—{C(=0)-0-CH2})q— formula II each n independently is an integer from 1-30; m is an integer from 1-10; q is 0 or 1. These compounds can be added to the lipid bilayer of thermosensitive liposomes, for the purpose of aiding in the prevention of leakage of the liposomes' contents at 37° C., and retarding clearance from circulation.

Abstract: Disclosed is a carrier for the local, targeted administration of a hydrophobic drug. The hydrophobic drug is rendered in to a hydrophilic prodrug thereof, and is contained in the lumen of a thermosensitive liposome or polymersome. Upon administration of the carrier, heat can be applied at the locus where the drug is to be released. After release of the prodrug, it will be activated so as to turn into the active drug.

Abstract: Disclosed are carriers for drugs and/or MR imaging agents having a lipid bilayer shell comprising a phospholipid having two terminal alkyl chains, one being a short chain having a chain length of at most seven carbon atoms, the other being a long chain having a chain length of at least fifteen carbon atoms. The mixed long/short chain phospholipids serve to tune the release properties of the carrier. Preferred phospholipids are phosphatidylcholines.

Abstract: The present invention relates to a composition comprising a shell structure forming a cavity, wherein said shell structure comprises a drug and wherein said composition is associated with at least one contrast agent; wherein said shell structure is capable of releasing its contents into the exterior upon the application of an external stimulus and wherein said contrast agent comprises magnetic particles which are capable of being detected by Magnetic Particle Imaging (MPI), wherein at least more than 5% (w/w) of the magnetic particles comprised in said contrast agent have a magnetic moment of at least ?18 m 2 A, 10 wherein said magnetic particles are preferably composed of Fe, Co, Ni, Zn or Mn or alloys thereof or oxides of any of these.

Abstract: The invention relates to a method of MR imaging of at least a portion of a body of a patient placed in an examination volume of an MR device. The object of the invention is to improve CEST contrast enhanced imaging. The method of the invention comprises the following steps: a) saturation of nuclear magnetization of exchangeable protons of a CEST contrast agent administered to the patient by subjecting the portion of the body to at least one frequency-selective saturation RF pulse matched to the MR frequency of exchangeable protons of the CEST contrast agent, wherein the saturation period, i.e.

Abstract: Described are drug carriers useful in magnetic resonance imaging (MRI)-guided drug release comprising a shell capable of releasing an enclosed biologically active agent as a result of a local stimulus, e.g. energy input, such as heat, wherein the shell encloses a 19F MR contrast agent. Preferably, the carrier also acts as a contrast enhancement agent for MRI based on the principle of Chemical Exchange-dependent Saturation Transfer (CEST). To this end the shell encloses a cavity that comprises a paramagnetic chemical shift reagent, a pool of proton analytes, and the 19F contrast agent, and wherein the shell allows diffusion of the proton analytes.

Abstract: Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with 5 the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T 1/T 2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.

Abstract: In magnetic resonance imaging (MRI) based on chemical exchange-dependent saturation transfer (CEST), a novel carrier for CEST contrast agents is provided. The carrier is non-spherical and comprises a semipermeable shell, wherein the shell comprises a paramagnetic compound. The shell encloses a cavitycomprising an MR analyte, wherein the semipermeable shell allows diffusion of the MR analyte. The CEST effect is based on the 5 bulk magnetic susceptibility effect caused by the anisotropy of the carrier. This leads to a versatile carrier that does not require interaction of the analyte with a paramgnetic chemical shift reagent.

Abstract: Described are Chemical Exchange-dependent Saturation Transfer (CEST) contrast agents for Magnetic Resonance Imaging (MRI) comprising a polymersome provided with a paramagnetic agent. The polymersome preferably comprises a polymeric shell enclosing a cavity, wherein the cavity comprises a pool of proton analytes, and wherein the shell allows diffusion of the proton analytes. The polymersome-based CEST MRI contrast agents are suitable as drug carriers useful in MRI-guided drug release.

Abstract: A process for production of a polyolefin-based composite material of high rigidity, containing a polyolefin and a layered clay, involves impregnating a layered, swellable clay which is interstratified with a tetraalkyl cation, with at least one polymerizable monomer and then mixing this impregnated clay with a polyolefin and a peroxide, at a temperature above the melting point of the polyolefin. A polyolefin-based composite material containing 98-50 wt. % of a polyolefin, 1-50 wt. % of another homo- or copolymer and 1-50 wt. % of a layered clay, wherein the ratio between the modulus of elasticity of the material and that of the initial polyolefin, at a temperature which is 30° C. below the melting temperature of the polyolefin, is higher than or equal to 1 has high rigidity.

Abstract: Extruded moulding prepared from a polyolefin-based composite material. The composite material comprises 98-50 wt % of a polyolefin, 1-50 wt % of another homo-or copolymer and 0.1-70 wt % of a layered, interstratified clay. The moulding normally contains 0.1-10 wt. % of the clay and can be aftertreated after extrusion.